Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas reported strong Q1 2024 financial results along with key corporate updates. The company continued enrollment in multiple clinical studies of vepdegestrant in metastatic breast cancer, progressed ARV-102 for neurodegenerative diseases, and entered a lucrative transaction with Novartis. The strategic deal includes an exclusive license for ARV-766 and sale of the preclinical AR-V7 program, with significant upfront payment and potential milestone payments. Arvinas also made key appointments in its management team and remains on track with its Phase 3 clinical programs. Financially, the company's cash position is strong, with enough funding to support planned operations until 2027.
Arvinas, Inc. (Nasdaq: ARVN) will be presenting at two investor conferences: the BofA Securities 2024 Healthcare Conference on May 14 and the UBS Spring Biotech Conferences on May 21. The company's Chief Medical Officer and Chief Business Officer will participate in various discussions and meetings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.